摘要
目的:探讨大麻素(WIN55,212-2)点眼治疗是否可以抑制慢性青光眼兔模型玻璃体谷氨酸浓度的增高。方法:家兔15只随机分为正常对照组,高眼压组和大麻素治疗组每组均5只10眼。除正常对照组以外均予前房注射复方卡波姆制成慢性青光眼模型。成功造模4d后,高眼压组用生理盐水点眼,大麻素治疗组用1.25g/L的大麻素滴眼液点眼。治疗4wk后取材,检测玻璃体谷氨酸浓度。结果:高眼压组的玻璃体谷氨酸浓度明显高于正常对照组,差异有统计学意义(高眼压组vs正常对照组,P<0.05),大麻素治疗组与正常对照组比较差异无统计学意义(大麻素治疗组vs正常对照组,P>0.05)。结论:局部应用WIN55,212-2可以使慢性青光眼兔模型玻璃体谷氨酸浓度降低。
AIM：To evaluate if the cannabinoid（WIN55,212-2）could lower the glutamic acid concentration in vitreous body by topical application（eyedrop）to chronic glaucoma rabbit model.METHODS：Fifteen rabbits were randomly divided into three groups with five rabbits（10 eyes）in each group.All the rabbits were made into chronic glaucoma model except the normal control group.After 7 days,the high intraocular pressure（IOP）group and the cannabinoid group were administered with normal saline and 1.25g/L WIN55-212-2 eyedrops repectively.The changes in the glutamic acid concentration in vitreous body were observed and quantified.RESULTS：There was significant difference in the glutamic acid concentration in vitreous body between high IOP group and normal control group（P〈0.05）,but no significant difference between cannabinoid group and normal control group（P〉0.05）.CONCLUSION：Cannabinoid topical application can lower the glutamic acid concentration in vitreous body that was increased by high IOP in chronic glaucoma rabbit model.
出处
《国际眼科杂志》
CAS
2008年第4期726-728,共3页
International Eye Science
